EU and FDA Inspected & Approved Manufacturing Facilities
Byondis has in-house Good Manufacturing Practice (GMP) manufacturing and conjugation facilities for both mAbs and ADCs, right up to early commercial launch scale.
Our team of approximately 200 highly qualified employees work in our state-of-the art research and development and GMP production facilities in Nijmegen, the Netherlands. Our activities span across 73,000 square meters, combining leading expertise in precision oncology drug development with proven GMP delivery capabilities.
Our Science
We employ the latest insights in tumor biology and immunology in our search for new molecular targets and development of new mechanisms for antibody-drug conjugates (ADCs) and small molecule programs.
Investors & Media
Byondis is a fully integrated biotech research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates.
